NOVN

Novartis AG

A Swiss pharmaceutical company that develops and sells medicines for conditions like heart failure, immune disorders, and cancer, including the brands Entresto, Cosentyx, and Kisqali. It was created in 1996 when the Basel giants Ciba-Geigy and Sandoz merged — at the time the largest corporate merger in history — with roots reaching back over two and a half centuries. Its name comes from the Latin phrase "novae artes," meaning "new skills."

• US pricing reforms, including the IRA and a voluntary 'most-favored-nation' agreement, are forcing significant price concessions on key drugs like Entresto, Cosentyx, and Kisqali.
• The loss of US market exclusivity for Entresto in July 2025 has already caused a substantial sales decline, with further revenue erosion expected from upcoming patent expiries.
• Proposed US tariffs on pharmaceuticals, though temporarily relieved for Novartis, could disrupt its supply chain and materially impact financial results if imposed.
• Intensifying competition and the inherent high failure rate of drug development threaten the company's ability to replace revenue lost to generics and biosimilars.
• The company faces significant operational risks from cybersecurity threats, complex IT system overhauls, and the challenge of integrating multiple recent acquisitions.
• Geopolitical instability and macroeconomic pressures, including inflation and potential recessions, are increasing cost-containment measures by payers and straining patient affordability.